Efficacy Results of a SURPASS open-label, phase III trial, published in 2021, demonstrated tirzepatides superior glycaemic efficacy and weight reduction compared with existing GLP-1 receptor agonists, including semaglutide 6
Wegovy, another Novo Nordisk semaglutide, is FDA-approved specifically for weight loss, showcasing promising results
The shortage caused people to lean on drugs like Ozempic off-label for weight loss
Proper reconstitution technique for compounded formulations is essential for those using non-brand preparations, and tools like the unit-to-milligram conversion guides and the comprehensive units-to-mg calculator eliminate dosing confusion
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Side effects and results vary